Evidence map›Paper›PMID 41288782›Full record

ArticleBreast cancer research and treatment2025

Mesothelin-expressing triple-negative breast cancer: a highly invasive and immunosuppressive subtype.

Zuxuan Zhao, Huizi Lei, Bingzhi Wang, Lei Guo, Lina Gao, Bingning Wang, Shan Zheng, Jianming Ying

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zuxuan Zhao *Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Huizi Lei *Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Bingzhi Wang *Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Lei GuoDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Lina GaoDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Bingning WangDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Shan ZhengDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. zhengshan@cicams.ac.cn.
Jianming YingDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. jmying@cicams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTriple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited therapeutic options. Mesothelin (MSLN), a tumor-associated antigen with potential targeted drugs, has been reported to be positive in some TNBC patients. However, there is a lack of studies on the clinicopathological characteristics of MSLN-expressing TNBC. MATERIALS AND

methodsWe first demonstrated the significance of MSLN through pan-cancer analysis. We utilized local cohort to demonstrated that MSLN is associated with an immunosuppressive microenvironment and patients with high MSLN expression have poorer response to neoadjuvant chemotherapy combined with immunotherapy. Moreover, MSLN-expressing TNBC exhibit extensive lymphovascular tumor thrombi. Furthermore, spatial transcriptomics investigated T1N3-stage TNBC and identified MSLN as a highly expressed target in this aggressive subtype, public single-cell data identified MSLN-expressing tumor sub-cluster and their characteristics.

conclusionThis study provides novel insights into the role of MSLN in TNBC and lays the foundation for future therapeutic strategies targeting MSLN in this aggressive breast cancer subtype.

Indexed as

Biomarkers, TumorGPI-Linked ProteinsTriple Negative Breast NeoplasmsFemaleHumansMesothelinMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisTumor MicroenvironmentBiomarkers, TumorGPI-Linked ProteinsMesothelinMSLN protein, humanImmunosuppressive microenvironmentLymphovascular tumor thrombiMesothelinMSLNTriple-negative breast cancer

Identifiers

PMID41288782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.